Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94727Review ArticleUndesirable effects of non-steroidal anti-inflammatory drugs: possible options for resolving the situationKotovaO. Vol_kotova@mail.ruAkarachkovaE. Snevrorus@mail.ruI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation19022017192-2859028122021Copyright © 2017, Consilium Medicum2017Non-steroidal anti-inflammatory drugs (NSAIDs) have many serious, potentially life-threatening adverse reactions or adverse events, but still belong to the most widely prescribed and used medications worldwide. In developed countries, these drugs are received by 20-30% of the elderly, among whom about 30% of the elderly are forced to take these drugs, despite the presence of risk factors for the development of adverse events, both from the gastrointestinal tract and the cardiovascular system. The article describes the side effects of NSAIDs. An alternative NSAID treatment for patients in need of analgesic therapy is suggested, flupirtine (Nolodatak). Flupirtine belongs to a fundamentally new class of drugs for the treatment of pain syndromes, it is a selective activator of neuronal potassium channels. Flupirtine is a non-opioid analgesic, which has an antispastic effect on the striated muscle. Nolodactak is produced by the company Akrikhin (capsules 100 mg) and bioequivalent to the original flupirtin (capsules 100 mg - Pliva Krakow, Pharmaceutical Plant AO, Poland).nonsteroidal anti-inflammatory drugsundesirable phenomenaflupirtineNolodatakнестероидные противовоспалительные препаратынежелательные явленияфлупиртинНолодатак[Котова О.В., Акарачкова Е.С., Данилов А.Б. Вопросы длительной терапии болевых синдромов. Рус. мед. журн. 2015; 23 (30): 16-8.][Wolfe M.M, Lichtenstein D.R, Singh G. Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs. N Engl J Med 1999; 340: 1888-91.][Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих НПВП: влияние стандартных факторов риска. Терапевт. арх. 2008; 5: 62-6.][Varga Z, Sabzwari S.R.A, Vargova V. Cardiovascular Risk of Nonsteroidal Anti - Inflammatory Drugs: An Under - Recognized Public Health Issue. Cureus 2017; 9 (4): e1144. DOI: 10.7759/cureus.1144][Walshe J.J, Venuto R.C. Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979; 91: 47-9.][Cannon P.J. Prostaglandins in congestive heart failure and the effects of non steroidal anti - inflammatory drugs. Am J Med 1986; 81: 123-32.][Bombardier C, Laine L, Reicin R. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000; 343: 1520-28.][Süleyman H, Demircan B, Karagöz Y. Anti - inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59: 3: 247-58.][Котова О.В. НПВП: в поисках золотой середины - соотношение безопасность/эффективность // Справочник поликлинического врача. 2013; 1: 15-8.][Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Nat Acad Sci USA 1992; 89: 7384-88.][Seibert K, Zhang Y, Leahy K et al. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A: 167-70.][Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Nat Acad Sci USA 1994; 91: 12013-17.][Mitchell J.A, Warner T.D. Cyclooxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999; 128: 1121-32.][Smith W.L, De Witt D.L, Garavito R.M. Cyclooxygenases: structural, cellular and molecular biology. Ann Rev Biochem 2000; 69: 145-82.][Radford M.G, Holley K.E, Grande J.P et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti - inflammatory drugs. JAMA 1996; 276: 466-8.][Насонова В.А. Клиническая оценка нестероидных противовоспалительных препаратов в конце ХХ века. РМЖ. 2000; 8 (17): 714-7.][Zeidler H, Kaltwasser J, Leonard J et al. Prescription and tolerability of meloxicam in day - to - day practice. Postmarketing observational cohort study of 13.307 patients in Germany. J Clin Rheumatol 2002; 8: 305-15.][Котова О.В. Вопросы безопасности длительной терапии нимесулидом. Фарматека. 2013; 9 (262): 54-8.][Garcia-Rodriguez L.A, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non - steroidal anti - inflammatory drugs. Lancet 1994; 343: 769-72.][Mc Donald T.M, Morant S.V, Robinson G.C et al. Association of upper gastrointestinal toxicity of non - steroidal anti - inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7.][Silverstein F.E, Graham D.Y, Senior J.R et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti - inflammatory drugs. A randomized, double - blind, placebo - controlled trial. Ann Intern Med 1995; 123: 241-9.][Bresalier R, Sandler R, Quan H et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 2005; 352: 1092-102.][Merck announces voluntary worldwide withdrawal of VIOXX. http://www.vioxx.com/vioxx/ documents/english/hcp_notification_physicians.pdf][Nissen S.E, Yeomans N.D, Solomon D.H et al. Cardiovascular safety of celecoxib, naproxen, oribuprofen for arthritis. N Engl J Med 2016; 375: 2519-29.][Михайлов И.Б. Настольная книга врача по клинической фармакологии. Руководство для врачей. СПб.: Фолиант, 2001; с. 736.][Johnson A.G, Nguyen T.V, Day R.O. Do nonsteroidal anti - inflammatory drugs affect blood pressure? A meta - analysis. Ann Intern Med 1994; 121: 289-300.][Aw T.J, Haas S, Liew D. Meta - analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.][Mc Gettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: asystematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006; 296: 1633-44.][Strom B.L, Carson J.L, Schinnar R et al. Nonsteroidal anti - inflammatory drugs and neutropenia. Arch Intern Med 1993; 153: 2119-22.][Patton W, Duffull S. Idiosyncratic drug - induced hematological abnormalities. Drug Safety 1994; 11 (6): 445-62.][Зборовский А.Б., Тюренков И.Н. Осложнения фармакотерапии. М.: Медицина, 2003.][Harrington L.S, Lucas R, Mc Master S.K et al. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin - sensitive asthma. FASEB J 2008; 22 (11): 4005-10.][Teoh N.C, Farrell G.C. Hepatotoxicity associated with non - steroidal anti - inflammatory drugs. Clin Liver Dis 2003; 7: 401-13.][Bort R, Ponsoda X, Jover R et al. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999; 288 (1): 65-72.][Palmer R, Weiss R, Zusman R.M et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003; 16: 135-9.][Schwartz J.I, Vandormael K, Malice M.P et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal salt diet. Clin Pharmacol Ther 2002; 72: 50-61.][Murray M.D, Brater D.C, Tierney W.M. Ibuprofen - associated renal impairment in a large general internal medicine practice. Am J Med Sci 1990; 299: 222-9.][Pathan E, Gaitonde S, Rajadhyaksha S et al. A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India 2003; 51: 1045-9.][Galesic K, Morovic-Vergles J. Drug - induced acute interstitial nephritis. Reumatizam 2003; 50 (1): 14-7.][Ueberall M, Mueller-Schwefe G, Terhaag B. Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain - results of a patient level, pooled re - analysis of randomized, double - blind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637-47.][Perovic S, Pialoglou P, Schroder H.C et al. Flupirtine increases the levels of glutathione and Bc1-2 in hNT (human Ntera/D1) neurons: mode of action of the drug - mediated anti - apoptotic effect. Eur J Pharmacol 1996; 12: 157-64.][Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333-38.][Wörz R, Müller-Schwefe G, Stroehmann I et al. Back pain: Guidelines for drug therapy. Fortschr Med 2000; 142 (5): 27-33.][Котова О.В., Акарачкова Е.С. Боль в шее: распространенность, факторы возникновения, возможности терапии. Фарматека. 2014; 9: 45-9.][Котова О.В. Острая боль в нижней части спины: не дать болезни затянуться. Фарматека. 2012; 14 (247): 60-4.][Herrmann W, Hiersemenzel R, Aigner M et al. Long - term tolerance of flupirtine. Open multicenter study over one year. Fortschr Med 1993; 111 (15): 266-70.][Mueller-Schwefe G. Flupirtine in acute and chronicpain associated with мuscle tenseness. Results of a postmarketing surveillance study. Forschr Med 2003; 121: 3-10.][Müller-Schwefe G, Uberall M. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Result of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008; 4: 153-61.][Singal R, Gupta P, Jain N, Gupta S. Role of flupirtine in the treatment of pain - chemistry and its effects. Maedica (Buchar) 2012; 7 (2): 163-6.][Котова О.В., Акарачкова Е.С. Место препарата Нолодатака в лечении боли в спине. Фарматека. 2015; 13: 70-3.]